Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $959.4 million.

  • Revolution Medicines' Cash from Financing Activities fell 102.06% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 22.13%. This contributed to the annual value of $959.4 million for FY2024, which is 21.95% down from last year.
  • Latest data reveals that Revolution Medicines reported Cash from Financing Activities of $959.4 million as of FY2024, which was down 21.95% from $1.2 billion recorded in FY2023.
  • In the past 5 years, Revolution Medicines' Cash from Financing Activities ranged from a high of $1.2 billion in FY2023 and a low of $294.2 million during FY2021.
  • In the last 3 years, Revolution Medicines' Cash from Financing Activities had a median value of $959.4 million in 2024 and averaged $830.0 million.
  • As far as peak fluctuations go, Revolution Medicines' Cash from Financing Activities spiked by 328.53% in 2020, and later slumped by 30.42% in 2021.
  • Revolution Medicines' Cash from Financing Activities (Yearly) stood at $422.8 million in 2020, then plummeted by 30.42% to $294.2 million in 2021, then grew by 2.47% to $301.4 million in 2022, then skyrocketed by 307.79% to $1.2 billion in 2023, then declined by 21.95% to $959.4 million in 2024.